AI-Sight – a University of Liverpool AI diagnostic technology spinout based at Sci-Tech Daresbury – has concluded a seven-figure equity funding round.
The funding comes from experienced healthcare industry figures and investors including Sir Michael Bibby (chairman of the Bibby Line Group), Phil Kirby (former managing director of InHealth Intelligence), Pitalia Capital (the family office of Anil Pitalia, founder of ophthalmology specialist SpaMedica) and Deepbridge Capital.
It will support MHRA approval and Class 2 certification for AI-Sight’s full diagnostic platform, as well as its launch in the UK and internationally.
The platform is designed to improve patient outcomes, with additional benefits that promote efficiency in public health systems and ensure human resources are allocated to the areas of greatest need.
This follows the Class 1 medical device certification of AI-Sight’s first commercial product. The AI software device is designed to support training and diagnostic decision-making by human graders of diabetic retinopathy in retinal scans.
As part of its membership of Sci-Tech Daresbury’s Future Club programme – the Liverpool City Region campus’ leading corporate growth scheme – AI-Sight has benefited from early access to the business growth programmes, partnerships and communities at the campus, along with office, laboratory and workshop facilities.
Dr Steve Powell, CEO said: “This latest funding milestone would not have been possible without the support of the team at Sci-Tech Daresbury. The Future Club programme has been instrumental in us making the connections that have enabled our growth to date.”
John Leake, business growth director at Sci-Tech Daresbury, added: “AI-Sight represent what the Future Club and our campus as a whole sets out to achieve – a winning combination of science and enterprise that endeavours to improve the world around us while driving economic growth.
“This latest funding round is a very exciting moment for the business, but what’s more pleasing is that the company is just at the start of its journey. We look forward to supporting AI-Sight as it continues its vital work.”